Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine

Pediatric Infectious Disease Journal

Volumn 23, Issue 12, 2004, Pages 1109-1115

  Tejedor, Juan C ^a   Omeñaca, Félix ^b   García Sicilia, José ^b   Verdaguer, Joaquim ^d   Van Esso, Diego ^e   Esporrin, Carlos ⁱ   Molina, Vicente ^f   Muro, Marta ^c   Marés, Josep ^j   Enrubia, Manuel ^g   Moraga, Fernando ^h   García Corbeira, Pilar ^k,m   Dobbelaere, Kurt ^l   Schuerman, Lode ^l  

^a HOSPITAL DE MÓSTOLES   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^d Hospital de Sant Llàtzer Terrassa   (Spain)

^e ABS Serraparera   (Spain)

^f INSTITUT UNIVERSITARI DEXEUS   (Spain)

^g ABS Anoia Rural   (Spain)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ HOSPITAL SANTA CATERINA   (Spain)

^j Institut Pediatric Mares Riera   (Spain)

^k GLAXOSMITHKLINE   (Spain)

^l GSK   (Belgium)

^m Glaxo SmithKline   (Spain)

more..

Author keywords

Concomitant administration; Hexavalent diphtheria tetanus toxoids acellular pertussis hepatitis B virus inactivated poliovirus Haemophilus influenzae type b (DTPa HBV IPV Hib) vaccine; Meningococcal C vaccine conjugate

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; MENINGOCOCCUS VACCINE; BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; DTPA HBV IPV COMBINED VACCINE; DTPA-HBV-IPV COMBINED VACCINE; HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE VACCINE; HAEMOPHILUS VACCINE; SEROGROUP C MENINGOCOCCAL CONJUGATE VACCINE; VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; APPETITE DISORDER; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DROWSINESS; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; EDEMA; FEMALE; FEVER; HEPATITIS B; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; INJECTION SITE; INJECTION SITE REACTION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MULTICENTER STUDY; NEISSERIA MENINGITIDIS; OPEN STUDY; PAIN; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; SIDE EFFECT; TETANUS; VACCINATION; BLOOD; IMMUNOLOGY;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; FEMALE; HAEMOPHILUS VACCINES; HUMANS; INFANT; MALE; MENINGOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; VACCINES, COMBINED;

EID: 20444498230     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000145427.19167.35     Document Type: Article

References (24)

1. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 2000;13:302-317.
2. Van Damme P, Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. J Med Virol. 2002;67:433-439.
3. Committee on Infectious Diseases. Recommended childhood immunization schedule: United States, 2002. Pediatrics. 2002;109:162.
4. Recommended childhood and adolescent immunization schedule: United States, January-June 2004. MMWR. 2004;53:Q1-Q4.
5. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. Wkly Epidemiol Rec. 2002;77:331-339.
6. Avdicová M, Prikazsky V, Hudecková H, Schuerman L, Willems P. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared with separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur J Pediatr. 2002;161:581-587.
7. Zepp F, Knuf M, Heininger U, et al. Safety, reactogenicity, and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary vaccination of infants. Vaccine. 2004;22:2226-2233.
8. Schmitt HJ, Knuf M, Ortiz E, Sanger R, Uwamwezi MC, Kaufhold A. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr. 2000;137:304-312.
9. Bramley JC, Hall T, Finn A, et al. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. Vaccine. 2001;19:2924-2931.
10. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementing of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2002;20 (suppl 1):S58-S67.
11. Lakshman R, Jones I, Walker D, et al. Safety of a new conjugate meningococcal C vaccine in infants. Arch Dis Child. 2001;85:391-397.
12. Salleras L., Dominguez A., Cardenosa N. Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccine. Vaccine. 2003;21:729-733.
13. Cartwright K, Noah N, Peltola H, Meningococcal Disease Advisory Board. Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. In: European Advisory Board Meeting Vienna, Austria, October 6-8, 2000. Vaccine. 2001;19:4347-4356.
14. Van Savage J, Decker MD, Edwards KM, Sell SH, Karzon DT. Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis. 1990;161:487-492.
15. Chan ISF, Zhang Z. Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics. 1999;55:1202-1209.
16. Halperin SA, McDonald J, Samson L, et al. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivate poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study. Clin Invest Med. 2002;25:243-251.
17. Schmitt HJ, Faber J, Lorenz I, Schmöle-Thoma B, Ahlers N. Safety, reactogenicity, and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. Vaccine. 2003;21:3653-3662.
18. Pichichero ME, Deloria MA, Rennels MB, et al. Safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics. 1997;100:772-788.
19. Rennels MB, Deloria MA, Pichichero ME, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics. 2000;105:e12.
20. Koplan JP. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five dose series. MMWR. 2000;49(RR-13):1-8.
21. Pappenheimer AM Jr, Edsall G, Lawrence HS, Banton HJ. Study of reactions following administration of crude and purified diphtheria toxoid in an adult population. Am J Hyg. 1950;52:357-370.
22. Scheifele DW, Meekison W, Grace M, et al. Adverse reactions to the preschool (fifth) dose of adsorbed diphtheria-pertussis-tetanus vaccine in Canadian children. Can Med Assoc J. 1991;145:641-647.
23. James G, Longshore WA Jr, Hendry JL. Diphtheria immunization studies of students in an urban high school. Am J Hyg. 1951;53:178-201.
24. Scheifele DW, Halperin SA, Ferguson AC. Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens. Vaccine. 2001;19:4720-4726.